CRBP Stock Analysis: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$9.25
0.18 (1.98%)
▲
5d:
+12.12%
30d:
+22.68%
90d:
-7.31%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $9.25, which is considered extended relative to its 30-day fair value range of $7.60 to $8.67.
Technical Outlook: Technically, CRBP is in a uptrend. The price is approaching resistance at $8.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRBP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.30 (+281.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRBP is in a uptrend. The price is approaching resistance at $8.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRBP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.30 (+281.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.60 -
$8.67
Company Quality Score
56/100
(HOLD)
Options IV Signal
19th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+6.7% above its trading range)
- BULLISH: Options cheap (IV 19th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 281.6% below Wall St target ($35.30)
Trading Range Analysis
30-Day Trading Range
$7.60 -
$8.67
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.55
(16.8%)
Support & Resistance Levels
Support Level
$7.45
Resistance Level
$8.57
Current Trend
Uptrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$35.30
(+281.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Smethurst
SELL
3285 shares
2026-02-03
Ian Hodgson
SELL
2415 shares
2026-02-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
